Table 2.
Parkinson’s disease Clinical Information
| Serum | CSF | ||
|---|---|---|---|
| Samples, n. | 53 | 93 | |
| Disease duration, y | 7.9 ± 5.0 | 8.5 ± 5.7 | n.s. |
| LEDD | 809 ± 557 | 696 ± 462 | n.s. |
| Motor subtype | |||
| Tremor predominant | 11 | 20 | n.s. |
| PIGD | 25 | 59 | |
| Indeterminant | 4 | 3 | |
| H&Y stage | |||
| 1 | 6 | 6 | n.s. |
| 2 | 18 | 25 | |
| 3 | 27 | 52 | |
| 4 | 2 | 4 | |
| 5 | 0 | 1 | |
| UPDRS motor score | 22.4 ± 11.5 | 23.2 ± 12.0 | n.s. |
All data are mean ± standard deviation unless otherwise specified.
*
Fisher’s exact < 0.001.
**
p < 0.05.
Abbreviations: n.s., not significant; LEDD, levodopa equivalent daily dose; H&Y, Hoehn and Yahr; UPDRS, Unified Parkinson’s Disease Rating Scale.